Taiwanese contractor JHL Biotech signed a deal to help Affinita Biotech develop and manufacture antibody treatments for cancer, lining up for as much as $20 million over four years. Under the agreement, JHL will handle cell line development, manufacturing assistance and process development through its facilities in Taiwan and Wuhan, China. Affinita, headquartered in South San Francisco, is at work on preclinical therapies for a range of cancers. More
> Scottish service provider BioOutsource said its biologics-focused lab passed FDA inspection. News
> Trial tech firms DrugDev and Exostar are pairing up to co-market their services, offering a cloud-based data management product. Item